An Alternative Strategy as Quorum-Sensing Inhibitor: Pheromone-Guided Antimicrobial Peptides



Mankind fights microbial infections worldwide by using large quantities of antimicrobials (Geddes 2000). The success of these therapies in infectious diseases is largely based on the availability of antimicrobials that aim to kill target pathogens (Kohansk et al. 2010). Indeed, many bacterial infections can be treated effectively with antibiotics since Alexander Fleming discovered the first antibiotic penicillin in 1928 (Andersson and Hughes 2010). In the battles of fighting against microbial infections today, however, we have found ourselves facing a severe threat: many antibiotics have lost their effectiveness in treating infectious diseases due to the growing crisis of development of antibiotic-resistant microorganisms (Hogan and Kolter 2002; Hughes and Anderson 2012). Meanwhile, many conventionally available antimicrobials exhibit broad-spectral killing with regard to bacterial genera and species (Eckert et al. 2006). Such indiscriminate killing of microbes can disrupt the ecological balance of the indigenous microflora in a natural ecosystem, resulting in various negative clinical consequences (Eckert 2011). The problems resulting from broad-spectrum antimicrobials combined with the emergency of antibiotic resistance highlight the urgent need for new antimicrobials that selectively target specific pathogens but less likely promote antibiotic resistance. Currently, there are at least two major research areas where researchers aim to discover such new antimicrobials as alternatives. In one field, antimicrobial peptides (AMPs) have been rigorously investigated as alternatives to small-molecule antibiotics, mainly because of their ability to kill antibiotic-resistant pathogens (Jenssen et al. 2006; Brogden and Brogden 2011). In another field that is extensively studied in recent years, scientists actively search for natural and synthetic compounds that act as quorum-sensing inhibitors (QSI) targeting bacterial cell-cell signaling and its controlled pathogenic activities (LaSarre and Federie 2013). These compounds that quench quorum-sensing mechanisms are considered as promising alternatives to antibiotic-resistant microbes (Kalia and Purohit 2011). It is believed that QSIs target bacterial cell-cell signaling and coordinated activities required for infections, thereby, essentially disarming the bacteria and tipping the balance in favor of the host and allowing the immune system to clear the infectious pathogen (Li and Tian 2012). QSI therapies that specifically block bacterial quorum sensing can make the pathogens become “deaf,” “mute,” or “blind” rather than directly kill them. Therefore, QSI therapy may achieve the treatment but cause much less selective pressure to create resistant microbes (LaSarre and Federie 2013; Kalia 2013). More recently, a new class of antimicrobials, called pheromone-guided antimicrobial peptides (PG-AMP), has been developed as potential alternatives (Eckert et al. 2006a, b; Mai et al. 2011; Qiu et al. 2003, 2005). PG-AMPs are fusion peptides that consist of a targeting domain of a quorum-sensing signal pheromone from a specific pathogen and a killing domain of a known antimicrobial peptide. The targeting domain can guide such a fusion peptide to bind selectively to the target pathogen, leading to quorum-sensing interference and selective killing. Thereby, pheromone-guided AMPs have added an exciting opportunity to develop new antimicrobials that selectively target pathogens. However, pheromone-guided AMPs and their application as an alternative therapy are still in their infancy. This chapter briefly reviews the current advances in this field.


Antimicrobial Peptide Target Domain Killing Activity Fusion Peptide Human Saliva 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Antimicrobial peptides


Competence-stimulating peptide


Ethylenediaminetetraacetic acid


Nuclear magnetic resonance


Pheromone-guided antimicrobial peptide


Quorum-sensing inhibitor


  1. Andersson DI, Hughes D (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8:260–271PubMedGoogle Scholar
  2. Brogden KA (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3:238–250PubMedCrossRefGoogle Scholar
  3. Brogden NK, Brogden KA (2011) Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? Int J Antimicrob Agents 38:217–225PubMedPubMedCentralGoogle Scholar
  4. Eckert R (2011) Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development. Future Microbiol 6:635–651PubMedCrossRefGoogle Scholar
  5. Eckert R, Qi F, Yarbrough DK, He J, Anderson MH, Shi WY (2006a) Adding selectivity to antimicrobial peptides: rational design of a multidomain peptide against Pseudomonas spp. Antimicrob Agents Chemother 50:1480–1488PubMedCrossRefPubMedCentralGoogle Scholar
  6. Eckert R, He J, Yarbrough DK, Qi F, Anderson MH, Shi W (2006b) Targeted killing of Streptococcus mutans by a pheromone-guided “smart” antimicrobial peptide. Antimicrob Agents Chemother 50:3651–3657PubMedCrossRefPubMedCentralGoogle Scholar
  7. Franzman MR, Burnell KK, Dehkordi-Vakil FH, Guthmiller JM, Dawson DV, Brogden KA (2009) Targeted antimicrobial activity of a specific IgG-SMAP28 conjugate against Porphyromonas gingivalis in a mixed culture. Int J Antimicrob Agents 33:14–20PubMedCrossRefPubMedCentralGoogle Scholar
  8. Geddes A (2000) Infection in the twenty-first century: prediction and postulates. J Antimicrob Chemother 46:873–877PubMedCrossRefGoogle Scholar
  9. He J, Eckert R, Pharm T, Simanian MD, Hu C, Yarbrough DK, Qi F, Anderson MH, Shi W (2007) Novel synthetic antimicrobial peptides against Streptococcus mutans. Antimicrob Agents Chemother 51:1351–1358PubMedCrossRefPubMedCentralGoogle Scholar
  10. He J, Yarbrough DK, Kreth J, Anderson MH, Shi W, Eckert R (2010) Systematic approach to optimizing specifically targeted antimicrobial peptides against Streptococcus mutans. Antimicrob Agents Chemother 54:2143–2151PubMedCrossRefPubMedCentralGoogle Scholar
  11. Hogan D, Kolter R (2002) Why are bacteria refractory to antimicrobials? Curr Opin Microbiol 5:472–477PubMedCrossRefGoogle Scholar
  12. Hossain MS, Biswas I (2012) An extracellular protease, SepM, generates functional competence-stimulating peptide in Streptococcus mutans UA159. J Bacteriol 194:5886–5896PubMedCrossRefPubMedCentralGoogle Scholar
  13. Hughes D, Anderson DI (2012) Selection of resistance at lethal and non-lethal antibiotic concentrations. Curr Opin Microbiol 15:555–560PubMedCrossRefGoogle Scholar
  14. Jenssen H, Hamill P, Hancock REW (2006) Peptide antimicrobial agents. Clin Microbiol Rev 19:491–511PubMedCrossRefPubMedCentralGoogle Scholar
  15. Kalia VC (2013) Quorum sensing inhibitors: an overview. Biotechnol Adv 31:224–245PubMedCrossRefGoogle Scholar
  16. Kalia VC, Purohit HJ (2011) Quenching the quorum sensing system: potential antibacterial drug targets. Crit Rev Microbiol 37:121–140PubMedCrossRefGoogle Scholar
  17. Kaplan CW, Sim JH, Shah KR, Kolesnikova-Kaplan A, Shi WJ, Eckert R (2011) Selective membrane disruption: mode of action of C16G2, a specifically targeted antimicrobial peptide. Antimicrob Agents Chemother 55:3446–3452PubMedCrossRefPubMedCentralGoogle Scholar
  18. Kohansk MA, Dwyer DJ, Collins JJ (2010) How antibiotics kill bacteria: from targets to network. Nat Rev Microbiol 8:423–435CrossRefGoogle Scholar
  19. LaSarre B, Federie MJ (2013) Exploiting quorum sensing to confuse bacterial pathogens. Microbiol Mol Biol Rev 77:73–111PubMedCrossRefPubMedCentralGoogle Scholar
  20. Li YH, Tian XL (2012) Quorum sensing and bacterial social interactions in biofilms. Sensors 12:2519–2538PubMedCrossRefPubMedCentralGoogle Scholar
  21. Li L, He J, Eckert R, Yarbrough D, Lux R, Anderson MH, Shi W (2010) Design and characterization of an acid-activated antimicrobial peptide. Chem Biol Drug Des 75:127–132PubMedCrossRefPubMedCentralGoogle Scholar
  22. Mai J, Tian XL, Gallant JW, Merkley N, Biswas Z, Syvitski R, Douglas SE, Junqi Ling JQ, Li YH (2011) A novel target-specific, salt-resistant antimicrobial peptide against the cariogenic pathogen Streptococcus mutans. Antimicrob Agents Chemother 55:5205–5213PubMedCrossRefPubMedCentralGoogle Scholar
  23. Patrzykat A, Gallant JW, Seo JK, Pytyck J, Douglas SE (2003) Novel antimicrobial peptides derived from flatfish genes. Antimicrob Agents Chemother 47:2464–2470PubMedCrossRefPubMedCentralGoogle Scholar
  24. Qiu XQ, Wang H, Lu XF, Zhang J, Li SF, Cheng G, Wan L, Yang L, Zuo JY, Zhou YQ, Wang HY, Cheng X, Zhang SH, Ou ZR, Zhong ZC, Cheng JQ, Li YP, Wu GY (2003) An engineered multidomain bactericidal peptide as a model for targeted antibiotics against specific bacteria. Nat Biotechnol 21:1480–1485PubMedCrossRefGoogle Scholar
  25. Qiu XQ, Zhang J, Wang H, Wu GY (2005) A novel engineered peptide, a narrow-spectrum antibiotic, is effective against vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 49:1184–1189PubMedCrossRefPubMedCentralGoogle Scholar
  26. Sullivan R, Santarpia P, Lavender S, Gittins E, Liu Z, Anderson MH, He J, Shi W, Eckert R (2011) Clinical efficacy of a specifically targeted antimicrobial peptide mouth rinse: targeted elimination of Streptococcus mutans and prevention of demineralization. Caries Res 45:415–428PubMedCrossRefPubMedCentralGoogle Scholar
  27. Syeebny LM, Banoczy J, Baum BJ, Edgar WM, Epstein JB, Fox PC, Larmas M (1992) Saliva: its role in health and disease. Int Dent J 42(Suppl 2):291–304Google Scholar
  28. Syvitski RT, Tian XL, Sampara K, Salman A, Lee SF, Jakeman DL, Li YH (2007) Structure-activity analysis of quorum-sensing signaling peptides from Streptococcus mutans. J Bacteriol 189:1441–1450PubMedCrossRefPubMedCentralGoogle Scholar
  29. Tian XL, Syvitski RT, Liu T, Livingstone N, Jakeman DL, Li YH (2009) A method for structure-activity analysis of quorum-sensing signaling peptides from naturally transformable streptococci. Biol Proced Online 11:207–226PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  1. 1.Department of Applied Oral SciencesDalhousie UniversityHalifaxCanada
  2. 2.Department of Microbiology and ImmunologyDalhousie UniversityHalifaxCanada

Personalised recommendations